Update on Clinical and Community Research Activities

February 12, 2021

Dear Clinical and Community Research Colleagues,

The Colorado COVID-19 dial has downgraded the counties of Adams, Arapahoe, and Denver that surround the campus and Tri-County area to "Level Yellow." 

Infection rates have declined since their peak in late-November and early-December. As a result of this change, we are able to ramp up clinical research for review and scheduling of research visits for Groups 1-5. This change is effective February 19, but only for studies who have already been approved to resume research activity. 

Studies in any group which have not received prior research restart approval need to apply through the CU Anschutz Medical Campus research restart portal or UCHealth application process, as appropriate, before undertaking any in-person clinical research activity.

Studies in Groups 1-5 that have previously been approved to resume research protocols do not need to reapply to restart approved activities. 

Due to the high volume of ongoing COVID-19 vaccine and treatment trials, scheduling capacity at the UCHealth CTRC remains limited. UCHealth inpatient CTRC will begin accepting appointments for Groups 1-4 on February 19.  

Group 3 and 4 protocols cannot request overbooks and may only schedule visits that are available through the automated Scheduler process. Additionally, UCHealth outpatient CTRC users might find limited times available for scheduling. Refer to the CCTSI Research Restart website for full details. 

Activity that requires face-to-face contact in the community for research purposes can still apply to re-activate following the process detailed on this webpage.

Please be aware that some locations may be limited for clinical research activity based on capacity restrictions due to the COVID-19 situation regardless of study groupings. Please check directly with the location of your research for such restrictions.

The CU Anschutz Medical Campus leadership will continue to monitor statewide and local COVID-19 data and make future adjustments in clinical research restrictions as the data warrant.


Thomas Flaig, MD
Vice Chancellor for Research
University of Colorado Denver | Anschutz Medical Campus